Teva Pharmaceutical Industries Ltd. announced US Food and Drug Administration (FDA) approval and commercial launch of Anastrozole tablets 1 mg, the company's generic version of AstraZeneca's Arimidex. The product is indicated for treatment of certain forms of breast cancer in postmenopausal women.
The brand product had annual sales of approximately $916.8 million in the United States, based on IMS sales data.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company.